trending Market Intelligence /marketintelligence/en/news-insights/trending/DOUsuRyKQjBvatfLXLXkvw2 content esgSubNav
In This List

French biotech Innate files for $100M US IPO, concurrent global offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


French biotech Innate files for $100M US IPO, concurrent global offering

France-based Innate Pharma SA filed with the U.S. Securities and Exchange Commission for a $100 million IPO on the Nasdaq global market.

The company, which develops therapeutic antibodies that harness the immune system to fight cancer, is offering its American depositary shares, representing ordinary shares in the U.S. and a concurrent private placement of its ordinary shares in Europe and countries outside the U.S.

The company will list on the Nasdaq Global Market under the IPHA ticker. The company's ordinary shares are listed on the Euronext Paris under the ticker IPH.

Innate's pipeline of antibodies includes Lumoxiti, licensed from AstraZeneca PLC and approved by the U.S. Food and Drug Administration in September 2018 for the treatment of a type of blood cancer.

Citigroup, SVB Leerink and Evercore ISI are joint book-runners for the U.S. offering, and Citigroup is the global coordinator for the European private placement.